Zastosowanie cyklosporyny A we wrzodziejącym zapaleniu jelita grubego i autoimmunizacyjnym zapaleniu wątroby u dzieci

Abstract Cyclosporin A is an immunosuppressive cyclic peptide. It has not only been a milestone in a transplantology, but is also a treatment's option in gastrology and hepatology. Cyclosporin A primarily affects T lymphocytes activation and proliferation through a calcineurin inhibition. Cyclosporin's A pharmacokinetic features force a dose modification based on its blood concentration and expected therapeutic level. The most frequent adverse effects are renal function impairment, hypertension, and hirsutism. CsA is metabolized mainly in the liver by cytochrome P450 enzymes, hence many drug interactions may occur. Although CsA presents variable bioavailability and poses a threat of adverse effects development, it induces remission in refractory paediatric ulcerative colitis and autoimmune hepatitis.